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Background: In Europe, administration of an inhaled corticosteroid (ICS) combined with a long-acting β2 agonist is
approved in chronic obstructive pulmonary disease (COPD) patients with a pre-bronchodilator FEV1 < 60% predicted
normal, a history of repeated exacerbations, and who have significant symptoms despite regular bronchodilator
therapy. Minimal data are available on the use of the fluticasone propionate/salmeterol xinafoate combination (FSC)
in the real-life COPD setting and prescription compliance with the licensed specifications.
Methods: A French observational study was performed to describe the COPD population prescribed with FSC,
prescription modalities, and the coherence of prescription practices with the market authorized population. Data
were collected for patients initiating FSC treatment (500 μg fluticasone propionate, 50 μg salmeterol, dry powder
inhaler) prescribed by a general practitioner (GP) or a pulmonologist, using physician and patient questionnaires.
Results: A total of 710 patients were included, 352 by GPs and 358 by pulmonologists. Mean age was over
60 years, and 70% of patients were male. More than half were retired, and overweight or obese. Approximately half
were current smokers and one-third had cardiovascular comorbidities. According to both physician evaluation and
GOLD 2006 classification, the majority of patients (>75%) had moderate to very severe COPD. Strict compliance by
prescribing physicians with the market-approved population for dry powder inhaler SFC in COPD was low, notably
in ICS-naïve patients; all three conditions were fulfilled in less than a quarter of patients with prior ICS and less than
7% of ICS-naïve patients.
Conclusions: Prescription of dry powder inhaler SFC by GPs and pulmonologists has very low conformity with the
three conditions defining the licensed COPD population. Prescription practices need to be improved and
systematic FEV1 evaluation for COPD diagnosis and treatment management should be emphasized.
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The economic and social burden of chronic obstructive
pulmonary disease (COPD) is considerable, with a pro-
jection that COPD will be the third leading cause of
death by 2020 [1]. Pharmacologic management for pa-
tients suffering from COPD is based on the use of bron-
chodilators, associated or not with a corticosteroid [2].
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unless otherwise stated.treatment(s), their efficacy and tolerance, and patient
preference regarding inhalers. In the most recent GOLD
(Global initiative on Obstructive Lung Disease) global
strategy document, four patient categories are defined
(A, B, C and D) based on exacerbation risk and symp-
toms burden [2]. Exacerbation risk is assessed according
to GOLD category for forced expiratory volume in 1 sec-
ond (FEV1) and past history of exacerbations, while
symptoms burden is assessed by the modified Medical
Research Council (mMRC) dyspnea grading scale and/or
the COPD Assessment Test (CAT), based on the worst
case scenario. For patients with FEV1 < 50% predictedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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year or one hospitalization for COPD exacerbation or
both, combinations of inhaled corticosteroids (ICS) and
long-acting β2 agonists (LABA) are recommend among
first-line treatments.
Administration of the ICS fluticasone propionate with
the LABA salmeterol xinafoate (fluticasone /salmeterol
combination, FSC) with a dry powder inhaler was ap-
proved in Europe in 2003, at a dose of 500 μg fluticasone
propionate with 50 μg salmeterol twice daily for treatment
of COPD patients with a pre-bronchodilator FEV1 < 60%
predicted normal, a history of repeated exacerbations, and
who have significant symptoms despite regular bron-
chodilator therapy. The change of the FEV1 threshold
from <50% in the GOLD guidelines [2] to <60% was mainly
influenced by the TORCH study [3].
Coherence between published COPD guidelines and clin-
ical prescription practices in the real-world setting has been
brought into question [4-6]. Several reports highlight that a
high proportion of patients who are prescribed inhaled
medications, have not undergone spirometric testing to
confirm diagnosis and severity [7-11]. Data on FSC use in
the real-life COPD setting are scarce and co-therapies in
patients prescribed with this combination as long-term
treatment have not been reported.
Following a request by the French Health Authorities,
a national, prospective, population-based, observational
study was performed in adult COPD patients initiating
treatment with fluticasone propionate/salmeterol (500/
50 μg) administered with a dry powder inhaler, pre-
scribed by a general practitioner (GP) or pulmonologist.
The study purpose was twofold; the first step was to col-
lect data describing patient characteristics and treatment
modalities in this population, and to analyze the coher-
ence of the prescription population with the licensed
COPD population according to the Summary of Product
Characteristics (SPC). In the second step, clinical out-
comes after 12-months treatment with SFC in this popu-
lation were evaluated. The present article reports results
regarding the first of these two goals.
Methods
Study design
This was a prospective observational cohort study with
1-year follow-up in COPD patients initiating treatment
with FSC delivered via a dry powder inhaler (Seretide®
Diskus®, 500/50 μg). It was performed in France between
March 2008 and July 2009. Patients were included by
GPs and pulmonologists who were randomly selected
from a validated national database of all registered phy-
sicians (Cegedim). GPs agreeing to participate were re-
quested to include two to four consecutive eligible patients
and pulmonologists to include six to nine consecutive pa-
tients. Data were collected at inclusion and at routinefollow-up visits using physician questionnaires and patient
self-administered questionnaires. The study was approved
by the French Advisory Committee for Data Processing in
Health Research (CCTIRS) and the French Data Protection
Authority (CNIL) and was conducted in accordance with
the Declaration of Helsinki and local regulations (etrack
number: 108314). Signed informed consent was obtained
from all patients.
Patient population
To be eligible, patients had to be clinically diagnosed with
COPD, initiating FSC therapy prescribed by a GP or a pul-
monologist at inclusion, aged 40 years or older, and be
current or former smokers with a history of at least 15
pack-years. Patients were ineligible if they had asthma, tu-
berculosis, cystic fibrosis, any other pulmonary condition,
or cancer at inclusion, had received anticancer treatment
during the previous 3 years, or were participating in an-
other clinical or epidemiologic study.
Questionnaires and data collection
Patient data reported by the physician at inclusion in-
cluded sociodemographics, disease history (including
smoking) and the following cardiovascular comorbidi-
ties: (i) cardiovascular diseases including heart failure,
coronary heart disease, peripheral vascular disease, and
other cardiovascular diseases (e.g., arrhythmias, valve
diseases) but excluding metabolic risk factors (diabetes,
hypercholesterolemia); (ii) hypertension. In addition, spi-
rometric measurements, blood gas levels and weight
were recorded at inclusion and, when performed, at each
follow-up visit. Cough, expectoration, and wheezing dur-
ing the 3 months prior to inclusion or any follow-up
visits were reported, as well as dyspnea (modified MRC
scale). Other variables included exacerbations and their
management during the 12 months prior to inclusion or
between visits, along with COPD treatments (bronchodi-
lators, corticosteroids, antibiotics, physician and hospital
visits, vaccinations, non-drug therapies) over the same
period. On the day of enrollment, a patient self-
administered questionnaire was used to evaluate dyspnea
(Borg scale [12]) and quality of life (QoL; Clinical COPD
Questionnaire, CCQ) [13], on the basis of the week prior
to the visit. Demographics and practice data were col-
lected for physicians.
Evaluations and statistical analyses
A minimum of 267 patients per group (i.e., included by
GPs or by pulmonologists) was required to estimate the
frequency of any event occurring in about 50% of patients
with a 5% type I error and a precision (i.e. maximum vari-
ation allowed around the estimate) of 6%. COPD severity
was classified according to GOLD 2006 [14], taking into ac-
count FEV1, and to GOLD 2011 (which was not available
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count FEV1, dyspnea MRC score, and history of exacerba-
tions. Prescriptions were considered compliant with the
SPC when the following three conditions were fulfilled at
inclusion: 1) FEV1 < 60% predicted; 2) a history of repeated
exacerbations (at least two over the last year, defined as an
emergency department visit, hospitalization, or a course of
oral corticosteroids or antibiotics for respiratory problems);
3) significant symptoms despite regular bronchodilator
therapy alone (with a long-acting β2-mimetic or long-
acting anticholinergic agent).
Analyses were performed according to physician spe-
cialty using descriptive statistics. Data were further ana-
lyzed in terms of prior ICS intake versus ICS-naïve. A
conservative approach was used such that missing data
for FEV1, exacerbations and long-acting bronchodilators
criteria were considered as non-fulfillment of the SPC
criteria. A first sensitivity analysis was performed exclud-
ing patients without FEV1 data given the high propor-
tion of patients for whom this examination was not
performed, and a second analysis excluded prior re-
peated exacerbations, given that this is a composite cri-
terion and considered to be less reliable than other
criteria.
Agreement between investigator-assessed and GOLD
2006 classifications was evaluated with a weighted Kappa
test. Comparisons within GP or pulmonologist popula-
tions (ICS-naïve versus ICS-treated patients; including
versus non-including physicians) were performed usingFigure 1 Flow diagram of physician and patient populations.student’s t-tests and variance analysis (after a Levene test
for homogeneity of variance) for quantitative data. Nor-
mality was confirmed with histograms and Shapiro-Wilk
tests. Satterthwaite’s approximation or Kruskal-Wallis
tests were used in cases of unequal variance. Non-
parametric tests were applied in the absence of normal
distribution. A Wilcoxon test was used for paired series.
Chi2 or Fisher exact tests were used to compare qualita-
tive data. Significance comparisons of GP versus pulmo-
nologist patient populations were not performed given
that these populations were recruited in different set-
tings during partially different time periods. A signifi-
cance threshold of 0.05 was used and analyses were
performed with SAS (v.9.1, SAS Institute, North Caro-
lina USA).Results
Overall 6.3% of the GPs (419 of 6620) and 8.7% of pul-
monologists (177 of 2030) who were contacted agreed to
participate (Figure 1). Of them, 162 GPs and 88 pulmo-
nologists included at least one patient, with GPs includ-
ing a median of two patients while pulmonologists
included a median of 4.5 patients. A comparison of
demographic and practice characteristics of physicians
including patients with those of the national population
of physicians and also with physicians who agreed to
participate but did not include patients are provided in
Additional file 1.
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A total of 710 patients initiating an SFC prescription
were included, 352 by GPs and 358 by pulmonologists
(Figure 1). Sociodemographic and clinical characteristics
are presented in Table 1. Mean patient age was over
60 years and more than half of the included patients
were retired (61%) and overweight or obese (57%). Al-
most half the patients were current smokers and cardio-
vascular comorbidities were reported in approximately
one-third of the population. Some differences in charac-
teristics were apparent between the GP and pulmonologist
populations, with the latter having a higher proportion of
patients who were retired, male, had hypertension or cor-
onary heart disease, while fewer pulmonologist patients
were current smokers. See Additional file 2 for a descrip-
tion of differences in patient characteristics between pa-
tients participating versus those who did not.
COPD profile and therapeutic management
At inclusion, the majority of patients had moderate to
very severe COPD according to both the physician’s
judgment and the GOLD-defined severity of airflow ob-
struction [14] (Table 1). A higher proportion of patients
had very severe disease according to the GOLD criteria
versus investigator judgment, which was confirmed by
Kappa evaluations showing that agreement between the
physician and the GOLD evaluations was poor for GPs
(Kappa = 0.25) and moderate for pulmonologists (Kappa =
0.52). According to GOLD 2006 classification, pulmonolo-
gists included a higher proportion of patients with severe
to very severe disease relative to GPs. FEV1 data were avail-
able in 335 patients included by pulmonologists (94%), but
only 153 of the 352 patients included by GPs (43%, includ-
ing 8 patients with an aberrant result considered missing
in the analysis). Pulmonologist patients had a poorer mean
FEV1% predicted and worse dyspnea than patients in the
GP group. See Additional file 2 for a description of differ-
ences in baseline characteristics in GP patients with FEV1
available versus those without and for a comparison of
investigator-assessed COPD severity versus GOLD 2006
in patients with FEV1 data.
Chronic symptoms were common in both groups, with
over 80% having chronic cough, and approximately two-
thirds of patients had both daily expectorations and cough
(Table 1). QoL outcomes were mid-range and similar in the
two groups, although symptom scores were poorer in the
GP group. A history of repeated exacerbations was reported
in 63% of GP patients and 30% of pulmonologist patients.
Nonetheless, incidence of emergency department visits and
hospitalizations was low overall with in most cases no more
than one visit over 12 months, but were more common in
the pulmonologist group than the GP group (Table 2). Pa-
tients in the GP group were more likely to be prescribed
antibiotics and corticosteroids. Pneumococcal vaccinationshad been administered in less than half the population and
along with flu vaccines, were more common among GP pa-
tients than pulmonologist patients.
Prior COPD medication intake was reported in 76% of
GP patients and 67% of pulmonologist patients. Co-
administration of an ICS and a short-acting or long-
acting bronchodilator was the most common treatment,
reported in approximately half these patients (144 GP,
54%; 115 pulmonologist, 48%). The use of short-acting
and/or long-acting bronchodilators (mostly anticholiner-
gics) without ICS was reported in 35% of GP patients
and 48% of pulmonologist patients (Table 2). Approxi-
mately one-third of both patient populations had re-
ceived LABA with ICS.
Among the 710 patients included, a comparison of
ICS-naïve patients versus those with prior ICS showed
that for both GP and pulmonologist patients the ICS-
naïve patient population was older (p < 0.01), had more
severe COPD (investigator-assessed; p ≤ 0.0004), had
been diagnosed with COPD for longer (p < 0.0001), had
worse dyspnea (MRC and Borg; p ≤ 0.03) and total QoL
scores (p < 0.01), were less likely to have been vaccinated
(p < 0.001), have visited a specialist (p < 0.001), have re-
ceived oral corticosteroid (p < 0.0001) or antibiotics (p <
0.01). In addition, GP patients with prior ICS were less
likely to be current smokers (p = 0.01), more likely to
have FEV1 data available (p < 0.0001, although there was
no difference in FEV1 values). Pulmonologist patients
with prior ICS were more likely to be female (p < 0.01),
have lower percent predicated FEV1 (p < 0.01) and have
consulted a GP (p < 0.01). See Additional file 3 for rea-
sons for FSC prescription and further details of COPD
therapies.
Modalities of SFC prescription and compliance with
recommendations
The most common Seretide® Diskus® dose prescribed
was one inhalation of 500 μg fluticasone propionate/
50 μg salmeterol twice daily (72% of GP-included pa-
tients, 83% of pulmonologist patients). A dose of two in-
halations twice daily was prescribed in 23% of GP
patients and 12% of pulmonologist patients.
FSC use in COPD patients in the real-life context is
summarized in Table 3 in terms of compliance with the
SPC, and according to prior corticosteroid intake in all
patients irrespective of whether FEV1 data were available.
Among patients having received prior ICS, compliance
with at least one of the three marketing authorization
conditions for prescription was reported in over 90% of
patients for both GPs and pulmonologists, however
compliance with all three decreased to 16% of GP pa-
tients and 26% of pulmonologist patients. In ICS-naïve
patients, these proportions decreased to 73% (GP) and
80% (pulmonologist) of patients complying with at least





Age in years, mean (SD) 61.6 (11.4) 352 65.3 (11.5) 358
Male, N (%) 227 (64.5%) 352 269 (75.1%) 358
Professional status, N (%) 352 357
Working 122 (34.7%) 57 (16.0%)
Retired 186 (52.8%) 246 (68.9%)
Other 44 (12.5%) 54 (15.1%)
BMI (kg/m2), N (%) 349 358
Underweight (<18) 10 (2.9%) 25 (7.0%)
Normal (18–25) 131 (37.5%) 138 (38.5%)
Overweight (25–30) 133 (38.1%) 121 (33.8%)
Obese (≥ 30) 75 (21.5%) 74 (20.7%)
Current smoker, N (%) 195 (55.4%) 352 127 (35.6%) 357
Pulmonary hypertension, N (%) 12 (3.5%) 343 32 (9.2%) 348
≥1 cardiovascular comorbidity, N (%) 116 (33.0%) 352 138 (38.5%) 358
Heart failure 44 (12.5%) 43 (12.0%)
Coronary heart disease 35 (9.9%) 62 (17.3%)
Peripheral artery disease 48 (13.6%) 45 (12.6%)
Other1 35 (9.9%) 55 (15.4%)
COPD severity (investigator), N (%) 352 358
Mild 49 (13.9%) 14 (3.9%)
Moderate 197 (56.0%) 151 (42.2%)
Severe 100 (28.4%) 152 (42.4%)
Very severe 6 (1.7%) 41 (11.5%)
COPD severity (GOLD 2006), N (%) 137 323
Grade 1 (mild) 31 (22.6%) 16 (5.0%)
Grade 2 (moderate) 62 (45.3%) 183 (56.6%)
Grade 3 (severe) 13 (9.5%) 38 (11.8%)
Grade 4 (very severe) 31 (22.6%) 86 (26.6%)
COPD severity (GOLD 2011), N (%)2 136 319
Group A: Low risk, less symptoms 20 (14.7%) 71 (22.3%)
Group B: Low risk, more symptoms 15 (11.0%) 72 (22.6%)
Group C: High risk, less symptoms 45 (33.1%) 52 (16.3%)
Group D: High risk, more symptoms 56 (41.2%) 124 (38.9%)
Median time in years since diagnosis (range) 5.0 (0–40) 347 4.0 (0–30) 352
FEV1, mean (SD)
3
% predicted 60.5 (22.8) 145 53.6 (16.7) 334
Arterial blood gas (mmHg), mean (SD)
PaO2 72.4 (12.8) 79 70.0 (11.7) 221
PaCO2 42.1 (6.2) 66 41.2 (6.0) 218
Dyspnea (MRC grade), N (%) 349 353
1 (strenuous exercise) 58 (16.6%) 24 (6.8%)
2 (walking upstairs or uphill) 146 (41.8%) 114 (32.3%)
3 (walking on the flat) 96 (27.5%) 103 (29.2%)
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Table 1 Main sociodemographic characteristics at inclusion and clinical profile of COPD patients prescribed with FSC
(Continued)
4 (walking slowly) 35 (10.0%) 77 (21.8%)
5 (daily activities) 14 (4.0%) 35 (9.9%)
Chronic symptoms, N (%)4
Daily expectorations 261 (74.6%) 350 232 (65.4%) 355
Daily cough 307 (87.7%) 350 287 (81.1%) 354
Daily expectorations + cough 245 (70.0%) 350 224 (63.3%) 354
Quality of life (CCQ) score, median5 304 336
Symptoms 3.3 2.8
Functional status 2.5 2.3
Mental status 2.0 2.0
Total 2.7 2.4
History of repeated exacerbations, N (%)6 222 (63.1%) 352 106 (29.6%) 358
1Excluding vascular (hypertension) and metabolic conditions (diabetes, hypercholesterolemia).
2A: GOLD 1–2 and < 1 exacerbation/year, MRC < 2; B: GOLD 1–2 and < 1 exacerbation/year, MRC ≥ 2; C: GOLD 3–4 and/or ≥ 2 exacerbations/year, MRC < 2; D: GOLD
3–4 and/or ≥ 2 exacerbations/year, MRC ≥ 2 [15].
3An additional 8 GP patients had FEV1 results which were aberrant and were excluded from the analysis; for one pulmonologist patient only FEV1 (L) was available
(% FEV1 was missing).
4During the 3 months prior to initiation.
5During 7 days prior to initiation; score on a scale of 0 to 6 where 6 is the worst score.
6During the 12 months prior to initiation; exacerbation was defined as at least two of the following separated by at least 7 days over the last year: an emergency
department visit, hospitalization, or a course of oral corticosteroids or antibiotics for respiratory problems.
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with all three conditions. Compliance with the FEV1 <
60% predicted normal criteria, was considerably lower
in the GP group than the pulmonologist group. Con-
versely, patients included by pulmonologists were less
likely to have fulfilled the requirement of repeated
exacerbations.
Discussion
Knowledge of real-life use of ICS/LABA combinations in
the COPD setting allows for evaluation of the conform-
ity of current prescription practices with the licensed
COPD population. This can in turn be used to encour-
age appropriate changes in current practices to improve
standards of patient care. Limited data on the use of
FSC in the real-life setting have been published since the
addition of COPD to the original marketing
authorization for this combination based on three
double-blind randomized placebo-controlled studies
[16-18].
From the data obtained in this observational study of a
COPD population initiating treatment with FSC admin-
istered via a dry powder inhaler, the very low rates of
strict compliance with the three SPC criteria for pre-
scription, notably in ICS-naïve patients, clearly reveal
that prescribing French physicians do not adequately re-
spect the licensing conditions. Less than a quarter of the
patients with prior ICS and less than 7% of ICS-naïve
patients fulfilled all three conditions. Furthermore, a
small proportion of patients did not fulfill any of theconditions. When considering both two or three of the
conditions, conformance improves slightly, but is still
low, being reported in approximately two-thirds of pa-
tients with prior ICS, and one-third of ICS-naïve
patients.
While conformance was higher for pulmonologists
than GPs in terms of the number of conditions
respected and for the FEV1 and previous bronchodilator
criteria, overall rates were low for both medical special-
ties. In the case of GPs, the discrepancy between the li-
censed and real-life COPD populations is due at least in
part to the high rate of missing spirometry measure-
ments, with FEV1 data available for less than half of
these patients. This is coherent with several studies
worldwide reporting that only around a third to a half of
patients undergo spirometry testing for newly diagnosed
COPD or subsequently during follow-up [7,10,11,19,20].
The large proportion of missing data for FEV1 among
GP patients limits the assessment of concordance be-
tween prescription practices and marketing authoriza-
tions and guidelines. The conservative approach used
with missing data (i.e., absence of FEV1 considered non-
respect) may have artificially lowered the rate of con-
formance in the GP group. Supporting this, a sensitivity
analysis including only patients for whom FEV1 mea-
sures were available gave similar conformance rates be-
tween GPs and pulmonologists for this criterion
(Additional file 4). Of note, the profile of patients with-
out FEV1 measures showed them to be generally health-
ier than those with measures (younger, less severe
Table 2 Therapeutic management of COPD prior to initiating fluticasone/salmeterol
GPs N patients (n = 352) Pulmonologists N patients (n = 358)
General care, N (%)1
Consultation with GP 320 (91.4%) 350 251 (73.6%) 341
Consultation with specialist 173 (49.6%) 349 215 (60.6%) 355
Emergency visits 31 (8.9%) 348 53 (14.9%) 356
Hospitalizations 38 (10.9%) 350 71 (19.8%) 358
Oral corticosteroids 220 (63.0%) 349 120 (33.7%) 356
Antibiotics 289 (83.5%) 346 194 (54.6%) 355
Vaccination, N (%)
Flu1 264 (75.4%) 350 214 (60.1%) 355
Pneumococcus (within 5 years) 168 (48.1%) 349 106 (30.1%) 352
Prior medication, N (%) 2682 2392
Short-acting bronchodilator 37 (13.8%) 26 (10.9%)
Long-acting ± short-acting bronchodilator 57 (21.3%) 88 (36.9%)
ICS + long-acting bronchodilator 87 (32.5%) 92 (38.5%)
ICS ± short-acting bronchodilator 57 (21.3%) 23 (9.6%)
Other ICS combination 15 (5.6%) 6 (2.5%)
Other 15 (5.6%) 4 (1.6%)
Concomitant medication, N (%)3 1674 2584
Long-acting anticholinergic ± short-acting bronchodilator 53 (31.7%) 173 (67.1%)
Short-acting bronchodilator 81 (48.5%) 71 (27.5%)
Long-acting β-2 adrenergic agonist 18 (10.8%) 11 (4.3%)
Other ICS 15 (9.0%) 3 (1.2%)
1During the 12 months prior to inclusion.
2Missing data for 84 GP and 119 pulmonologist patients.
3At the time of FSC initiation.
4Missing data for 185 GP and 100 pulmonologist patients.
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It could also be hypothesized that perceived QoL is a
particularly important determinant of treatment deci-
sions by GPs. Indeed, health-related QoL as measured
by the CCQ was similar in pulmonologist and GP pa-
tients despite the latter patients having a lower dyspnea
grade, less pronounced airflow obstruction and less fre-
quent hospital visits. This illustrates that QoL measures,
even when specifically designed for COPD patients, capture
the impact of components other than those directly related
to COPD. Interestingly, GP patients were younger and less
likely to be retired than those treated by pulmonologists.
Thus, it could be hypothesized that their perception of the
disease’s impact is enhanced by their activity requirements,
although this possibility remains to be tested. It was also
noted that although pulmonologist patients are likely to
have more severe COPD, pulmonologists tend to be more
restrictive in the use of antibiotics and corticosteroids in pa-
tients treated in the community, as recommended in the
French COPD guidelines. In these guidelines, antibiotics
are recommended only when sputum is purulent, andcorticosteroids are to be prescribed only for patients with
severe baseline airflow obstruction and/or lack of im-
provement following treatment with antibiotics, if re-
quired, and bronchodilators.
Another potential reason for discrepancy between the
licensed and real-life COPD populations may lie with the
possibility that exacerbations were underestimated in this
study since they were only assessed from patient recall;
interestingly, conformance with this criterion was par-
ticularly low among pulmonologists. A low level of
overall conformity was maintained in a sensitivity ana-
lysis excluding this criterion. Difficulty evaluating prior
exacerbations stems from multiple sources; not only is
there an absence of consensus on the definition of
COPD exacerbations [21-23], but in addition, patients
tend to under-report exacerbations [24], even those that
have clinical significance [25].
Differences in conformity were seen according to prior
corticosteroid intake, with patients having prior ICS gen-
erally less likely to conform to prescription recommen-
dations relative to ICS-naïve patients. This may have
been influenced by the fact that prior ICS treatment may
Table 3 Compliance of practice patterns with FSC marketing conditions for prescription according to prior ICS intake,
irrespective of FEV1 availability









Approved prescription condition respected, N (%)
FEV1 < 60% predicted
1 53 (33.3%) 76 (63.3%) 28 (14.5%) 144 (60.5%)
History of repeated exacerbations 109 (68.6%) 51 (42.5%) 113 (58.5%) 55 (23.1%)
Continuous bronchodilator therapy 101 (63.5%) 97 (80.8%) 57 (29.5%) 89 (37.4%)
All conditions respected (regulatory approval criteria) 25 (15.7%) 31 (25.8%) 6 (3.1%) 16 (6.7%)
Details of conditions respected, N (%)
None 15 (9.4%) 6 (5.0%) 53 (27.5%) 47 (19.7%)
FEV1 only 5 (3.1%) 5 (4.2%) 9 (4.7%) 69 (29.0%)
Repeated exacerbations only 27 (17.0%) 2 (1.7%) 66 (34.2%) 13 (5.5%)
Continuous bronchodilator only 18 (11.3%) 28 (23.3%) 13 (6.7%) 28 (11.8%)
FEV1 and repeated exacerbations only 11 (6.9%) 10 (8.3%) 8 (4.1%) 20 (8.4%)
FEV1 and bronchodilators only 12 (7.5%) 30 (25.0%) 5 (2.6%) 39 (16.4%)
Repeated exacerbations and bronchodilators only 46 (28.9%) 8 (6.7%) 33 (17.1%) 6 (2.5%)
FEV1 and repeated exacerbations +/− bronchodilators 36 (22.6%) 41 (34.2%) 14 (7.3%) 36 (15.1%)
FEV1 or repeated exacerbations 126 (79.2%) 86 (71.7%) 127 (65.8%) 163 (68.5%)
N conditions respected, N (%)
At least one 144 (90.6%) 114 (95.0%) 140 (72.5%) 191 (80.3%)
At least two 94 (59.1%) 79 (65.8%) 52 (26.9%) 81 (34.0%)
1Missing FEV1 data were considered non-respect of condition.
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explained by the fact that this population was older, had
more severe and longer duration COPD, with a higher
incidence of oral corticosteroid and antibiotic intake.
Poor physician compliance with licensed conditions
may also reflect a level of difficulty in applying recom-
mendations and guidelines in the face of lack of clarity
or simplicity, or in the context of individualized patient
care. As reported by Corrado et al., recommendations
can be considered inappropriate if other factors such as
pulmonary hyperinflation, exercise capacity and toler-
ance, or comorbidities are not taken into account [27].
This may also explain the relatively high rates of incor-
rect dose prescription. Dialogue with physicians, along
with improved awareness and education are needed in
order to address these issues.
Analysis of populations and SPC conformance accord-
ing to the GOLD 2011 classification reveals some differ-
ences compared to GOLD 2006 classification. Very severe
airflow obstruction (GOLD grade 4) was reported in ap-
proximately one-quarter of the population while 40%
belonged to the D GOLD 2011 category. In nearly a quar-
ter of cases, GPs prescribed FSC to patients with GOLD
2006-defined mild COPD. This may be due to the fact that
they (along with pulmonologists) tended to underestimate
COPD severity relative to both 2006 and 2011 GOLDclassifications (notably for most severe disease). Compar-
ing the GOLD 2006 and 2011 classifications also shows
that according to the latter, GPs were more likely than
pulmonologists to see patients with more severe COPD
(74% versus 55%, respectively), which was not the case
with the 2006 guidelines (32% versus 38%, respectively).
Furthermore, according to the GOLD 2011 classification,
more patients have more severe disease, suggesting a
higher rate of conformity with the SPC licensing condi-
tions, and also that the guidelines may be evolving to
adapt to the real-life situation.
Another potential study limitation concerns the repre-
sentativeness of participating physicians. The low rate of
physicians selected randomly from the national population
who agreed to participate in the study (<10%) suggests a
general reluctance to participate and consequently a po-
tential selection bias. Nonetheless, participating physicians
were broadly representative of national figures for their
respective specialties in terms of age, gender and practice
settings [28], although male physicians were over-
represented relative to national figures. It could be hy-
pothesized that participating physicians were more likely
to be interested in the field of COPD and prescribe treat-
ments more adequately than less interested physicians.
As a consequence, the already very high rate of non-
concordance between prescriptions and guidelines could
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ing this pessimistic hypothesis.
Conclusions
The COPD population prescribed with FSC by both GPs
and pulmonologists conforms poorly with the licensed
population with less than a quarter of ICS-treated patients
and 7% of ICS-naïve patients fulfilling all three marketing
conditions. Prescribing clinicians need further education on
the importance of following the SPC recommendations, in-
cluding FEV1 evaluation, to ensure FSC is used only in
COPD patients who are likely to benefit from it. Under-
standing the reasons behind clinicians’ decisions to pre-
scribe FSC to non-conforming patients may help to resolve
this issue.
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